In the latest trading session,, 1.14 million Protara Therapeutics Inc (NASDAQ:TARA) shares changed hands as the company’s beta touched 1.68. With the company’s most recent per share price at $3.57 changed hands at -$0.75 or -17.36% at last look, the market valuation stands at $131.26M. TARA’s current price is a discount, trading about -193.56% off its 52-week high of $10.48. The share price had its 52-week low at $1.60, which suggests the last value was 55.18% up since then. When we look at Protara Therapeutics Inc’s average trading volume, we note the 10-day average is 0.47 million shares, with the 3-month average coming to 300.71K.
Analysts gave the Protara Therapeutics Inc (TARA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended TARA as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Protara Therapeutics Inc’s EPS for the current quarter is expected to be -0.48.
Protara Therapeutics Inc (NASDAQ:TARA) trade information
Instantly TARA was in red as seen in intraday trades today. With action -7.27%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -32.39%, with the 5-day performance at -7.27% in the red. However, in the 30-day time frame, Protara Therapeutics Inc (NASDAQ:TARA) is -21.37% down. Looking at the short shares, we see there were 2.03 million shares sold at short interest cover period of 7.82 days.
The consensus price target for the stock as assigned by Wall Street analysts is 12, meaning bulls need an upside of 70.25% from its recent market value. According to analyst projections, TARA’s forecast low is 12 with 12 as the target high. To hit the forecast high, the stock’s price needs a -236.13% plunge from its current level, while the stock would need to soar -236.13% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 55.31%. The 2025 estimates are for Protara Therapeutics Inc earnings to increase by 22.27%, but the outlook for the next 5-year period is at 2.40% per year.
TARA Dividends
Protara Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Mar-04.
Protara Therapeutics Inc (NASDAQ:TARA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.60% of Protara Therapeutics Inc shares while 86.79% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 90.03%. There are 86.79% institutions holding the Protara Therapeutics Inc stock share, with OPALEYE MANAGEMENT INC. the top institutional holder. As of 2024-06-30, the company held 20.1758% of the shares, roughly 2.3 million TARA shares worth $5.3 million.
RA CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 16.6361% or 1.9 million shares worth $3.95 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . With 1.02 shares estimated at $3.59 million under it, the former controlled 2.78% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held about 0.81% of the shares, roughly 296.0 shares worth around $1.04 million.
